Navigation Links
Beckman Coulter Announces Licensing Agreements for Molecular Tests with National University of Ireland, Galway
Date:1/22/2008

Contracts Give Access to Diagnostic Application of Research Technologies

FULLERTON, Calif., Jan. 22 /PRNewswire-FirstCall/ -- Beckman Coulter, Inc. (NYSE: BEC) announced today that it has signed four agreements with National University of Ireland, Galway (NUI Galway) to direct assay research and acquire licenses for intellectual property that will enable development of infectious disease tests for the company's future molecular diagnostic instrument. Under the terms of the three-to-five year agreements, research will begin in early 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO)

"With these agreements, we will take a big step toward the launch of our 'sample-to-result' molecular diagnostic system, including a differentiated menu of moderately complex tests that address urgent clinical decisions," commented Mike Whelan, group vice president of Beckman Coulter's High Sensitivity Testing Group. "The agreements give us access to intellectual property for the development of tests for infectious diseases including sepsis; hospital-acquired infections; and sexually transmitted diseases, such as Chlamydia and Neisseria." Infectious disease testing comprises about 50 percent of the $2 billion molecular diagnostics market in the United States.

The assay development research relies on NUI Galway nucleic acid detection technology for both bacterial and fungal targets along with SPRI(R) (Solid Phase Reversible Immobilization) and other technologies from Beckman Coulter.

Whelan added, "The combination of NUI Galway technologies with ours gives us a glimpse of the next generation of molecular diagnostics. Our goal is that our simplified, automated solution will allow these time-consuming, complex, and labor-intensive tests to migrate into the routine hospital lab. So physicians will get diagnostic information within hours, instead of days or weeks, and be able to begin treating patients much sooner."

Welcoming this new partnership with Beckman Coulter, Dr. Iognaid O Muircheartaigh, NUI Galway president, praised the work of the researchers leading this initiative. "These leading-edge researchers are addressing some of the most challenging and important issues at the frontier of modern biomedical research -- with the ultimate goal of changing the way patients are diagnosed. The research and technology development collaboration with Beckman Coulter is a strong endorsement from industry of the quality and importance of the research being undertaken at NUI Galway."

"We are excited to partner with Beckman Coulter on this unique initiative," said Dr. Daniel O'Mahony, director, Technology Transfer at NUI Galway. "It underpins our commitment to, and support of, research excellence and exemplifies our stated research strategy: creating an environment that values intellectual property, and promoting technology transfer and commercialization activity among University researchers and industry partners. This collaboration brings together molecular diagnostic expertise at NUI Galway with automated solution expertise at Beckman Coulter that will result in the development of break-through technologies for the diagnosis of a variety of infectious diseases in humans."

Established in 1845 as Queen's College Galway, National University of Ireland, Galway is one of Ireland's foremost centers of academic excellence. With more than 15,000 students, it has a long-established reputation of teaching and research excellence in each of its six colleges -- Arts, Social Sciences and Celtic Studies; Science; Law; Commerce; Engineering and Informatics; Medicine, Nursing and Health Sciences.

Beckman Coulter, Inc., based in Fullerton, California, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 200,000 Beckman Coulter systems operate in laboratories around the world supplying critical information for improving patient health and reducing the cost of care. Recurring revenue, consisting of supplies, test kits, service and operating-type lease payments, represents more than 75 percent of the company's 2006 annual revenue of $2.53 billion.
For more information, visit http://www.beckmancoulter.com.

Contacts: Mary Luthy

Corporate Communications, Beckman Coulter

Phone: (714) 993-8770

E-mail: mluthy@beckman.com

Allan Harris

Investor Relations, Beckman Coulter

Phone: (714) 773-7620

E-mail: adharris@beckman.com


'/>"/>
SOURCE Beckman Coulter, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Dec. 5, 2016   BIOTRONIK today announced ... The study evaluates the safety and feasibility of performing ... office setting. BioMonitor 2 is an insertable ... is placed underneath a patient,s skin to help physicians ... Atrial fibrillation is a leading cause of stroke and ...
(Date:12/5/2016)... , Dec. 5, 2016  Wellbridge Health and Gateway Health ... health solutions to Medicare and Medicaid plan members with specific ... at the unique needs of this group of consumers, Wellbridge ... work philosophies to provide insight into members, daily behaviors and ... , , ...
(Date:12/5/2016)... PARSIPPANY, N.J. , Dec. 5, 2016 /PRNewswire/ ... announced preliminary safety and efficacy data from a ... selective MDM2 inhibitor, suggesting that DS-3032 may be ... acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome ... of the phase 1 study of DS-3032 were presented ...
Breaking Medicine Technology:
(Date:12/5/2016)... ... December 05, 2016 , ... "FCPX Overlay Glare is a tool ... effect without heavy rendering or complicated compositing," said Christina Austin - CEO of Pixel ... an organic spectrum of lights that simulates the look of a glare. Just ...
(Date:12/5/2016)... ... December 06, 2016 , ... For many years, Andrew G. ... thick and thin. The beauty of the Lithuanian language and its poetry ... this poetry book, Zubinas lyrically explores all aspects of a living, breathing forest where ...
(Date:12/5/2016)... ... 2016 , ... Researchers at Johns Hopkins All Children’s Hospital want to learn ... the course of three years, researchers will study concussions and changes in brain function ... with special sensors, will track the location and force of the hit. The sensors ...
(Date:12/5/2016)... , ... December 05, 2016 , ... ... a patent-pending blend of L-Citrulline and glutathione to enhance production of nitric oxide ... that studies have shown to produce NO twice as effectively and sustains NO ...
(Date:12/5/2016)... , ... December 05, 2016 , ... ... and geographic lines. The goal of Castlewood Treatment Centers has always been to ... accessible to as many people as possible. In that spirit, Castlewood has announced ...
Breaking Medicine News(10 mins):